Vermont Collateral License Agreement between GeneLink, Inc. and The University of North Texas Health Science Center

• Category: Corporations - Public - Licenses
• State: Multi-State
• Control #: US-EG-9161
• Format: Word; Rich Text

Description

Collateral License Agreement between GeneLink, Inc. and The University of North Texas Health Science Center at Forth Worth dated July 1, 1996. 2 pages The Vermont Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center is a comprehensive legal contract that outlines the terms and conditions regarding the licensing of collateral materials and technology developed by the University to Gentling. This agreement is specifically designed to protect the intellectual property rights of the University while allowing Gentling to use and commercialize the collateral materials. It establishes a framework for the management, access, and transfer of technologies developed through collaborative research efforts. Some key provisions included in this agreement are: 1. Scope of the Agreement: The agreement clearly defines the materials and technologies covered under the license, ensuring both parties have a shared understanding of what can be used and commercialized. 2. Intellectual Property Rights: The agreement acknowledges and protects the University's intellectual property rights, allowing Gentling to use the collateral materials but ensuring that the University maintains control and ownership of its knowledge and discoveries. 3. Licensing and Royalty Fees: The agreement outlines the financial obligations of Gentling, including licensing fees and potential royalty payments. This ensures that the University receives fair compensation for the commercialization of its collateral materials and technologies. 4. Reporting and Auditing: Gentling is required to provide regular reports on the progress and status of commercialization efforts. The University has the right to audit these reports to ensure compliance with the agreement. 5. Confidentiality and Non-Disclosure: Both parties agree to keep any confidential information exchanged during the collaboration confidential, preventing unauthorized disclosure or use of proprietary data. 6. Term and Termination: The agreement specifies the duration of the license and the conditions under which either party can terminate the agreement. This ensures that both parties have clarity regarding the length and conditions of their collaboration. It is important to note that different types of Vermont Collateral License Agreements may exist between Gentling, Inc. and The University of North Texas Health Science Center, depending on the specific collateral materials and technologies being licensed. These agreements may differ in scope, terms, and financial arrangements based on the unique circumstances of each collaboration. Overall, the Vermont Collateral License Agreement serves as a legally binding document that governs the licensing and usage of collateral materials and technologies developed through collaborative research efforts between Gentling, Inc. and The University of North Texas Health Science Center. It establishes a framework for fair and equitable collaboration while protecting the intellectual property rights of the University.

The Vermont Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center is a comprehensive legal contract that outlines the terms and conditions regarding the licensing of collateral materials and technology developed by the University to Gentling. This agreement is specifically designed to protect the intellectual property rights of the University while allowing Gentling to use and commercialize the collateral materials. It establishes a framework for the management, access, and transfer of technologies developed through collaborative research efforts. Some key provisions included in this agreement are: 1. Scope of the Agreement: The agreement clearly defines the materials and technologies covered under the license, ensuring both parties have a shared understanding of what can be used and commercialized. 2. Intellectual Property Rights: The agreement acknowledges and protects the University's intellectual property rights, allowing Gentling to use the collateral materials but ensuring that the University maintains control and ownership of its knowledge and discoveries. 3. Licensing and Royalty Fees: The agreement outlines the financial obligations of Gentling, including licensing fees and potential royalty payments. This ensures that the University receives fair compensation for the commercialization of its collateral materials and technologies. 4. Reporting and Auditing: Gentling is required to provide regular reports on the progress and status of commercialization efforts. The University has the right to audit these reports to ensure compliance with the agreement. 5. Confidentiality and Non-Disclosure: Both parties agree to keep any confidential information exchanged during the collaboration confidential, preventing unauthorized disclosure or use of proprietary data. 6. Term and Termination: The agreement specifies the duration of the license and the conditions under which either party can terminate the agreement. This ensures that both parties have clarity regarding the length and conditions of their collaboration. It is important to note that different types of Vermont Collateral License Agreements may exist between Gentling, Inc. and The University of North Texas Health Science Center, depending on the specific collateral materials and technologies being licensed. These agreements may differ in scope, terms, and financial arrangements based on the unique circumstances of each collaboration. Overall, the Vermont Collateral License Agreement serves as a legally binding document that governs the licensing and usage of collateral materials and technologies developed through collaborative research efforts between Gentling, Inc. and The University of North Texas Health Science Center. It establishes a framework for fair and equitable collaboration while protecting the intellectual property rights of the University.